APA

Anderson M. A., Tam C., Lew T. E., Juneja S., Juneja M., Westerman D., Wall M., Lade S., Gorelik A., Huang D. C. S., Seymour J. F. & Roberts A. W. (20170828). Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. : Blood.

Chicago

Anderson Mary Ann, Tam Constantine, Lew Thomas E, Juneja Surender, Juneja Manu, Westerman David, Wall Meaghan, Lade Stephen, Gorelik Alexandra, Huang David C S, Seymour John F and Roberts Andrew W. 20170828. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. : Blood.

Harvard

Anderson M. A., Tam C., Lew T. E., Juneja S., Juneja M., Westerman D., Wall M., Lade S., Gorelik A., Huang D. C. S., Seymour J. F. and Roberts A. W. (20170828). Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. : Blood.

MLA

Anderson Mary Ann, Tam Constantine, Lew Thomas E, Juneja Surender, Juneja Manu, Westerman David, Wall Meaghan, Lade Stephen, Gorelik Alexandra, Huang David C S, Seymour John F and Roberts Andrew W. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. : Blood. 20170828.